COVID-19 Antibody Treatment Study Paused
ACTIV-3 study, testing use of an antibody therapy with remdesivir, paused 'out of an abundance of caution'
U.S. Deaths Up 20 Percent From March Through July 2020
The United States has had high COVID-19-associated mortality compared with other countries
Symptoms of COVID-19 Poor Marker for SARS-CoV-2 Infection
Only 13.9 percent of individuals with positive test reported specific symptoms on the day of the test
Bedside Tracheotomy Feasible for Critically Ill COVID-19 Patients
No infection identified among surgeons following procedure; postoperative complications rarely seen
CDC: U.S. COVID-19 Deaths Could Reach 233,000 by End of October
And, dual coronavirus-flu vaccine to start human trials
Remdesivir Cuts Time to COVID-19 Recovery
However, no significant difference in mortality found between remdesivir and placebo groups
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician's Briefing chose as the most important COVID-19 developments for you and your practice for the week of...
Remote Ischemic Postconditioning May Aid Stroke Recovery
More patients with acute ischemic stroke in RIPC group had excellent recovery at three months
Lifetime Prevalence of Suicide Ideation 17.4 Percent Among Doctors
Lifetime prevalence of suicide attempts 1.8 percent, with one-year prevalence of 0.3 percent
Maker of Antibody Cocktail Trump Took Seeks Emergency Use Authorization
Although effectiveness has not yet been seen in humans, drug has shown promise in treating mild cases of COVID-19
